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Abstract
The aim of the study was to evaluate the kinetic parameters of a
specific serotonin transporter (SERT) and serotonin uptake in a
mentally healthy subset of patients with fibromyalgia. Platelets
were obtained from 40 patients and 38 healthy controls. SERT
expression and functionality were evaluated through the
measurement of [3H]paroxetine binding and the [3H]serotonin
uptake itself. The values of maximal membrane binding capacity
(Bmax) were statistically lower in the patients than in the healthy
volunteers, whereas the dissociation constant (Kd) did not show
any statistically significant variations. Moreover, a decrease in
the maximal uptake rate of SERT (Vmax) was demonstrated in the
platelets of patients, whereas the Michaelis constant (Km) did
not show any statistically significant variations. Symptom
severity score (tiredness, tender points index and Fibromyalgia
Impact Questionnaire) were negatively correlated with Bmax and
with Vmax, and positively correlated with Km. A change in SERT
seems to occur in fibromyalgic patients, and it seems to be
related to the severity of fibromyalgic symptoms.
Introduction
Fibromyalgia syndrome (FMs) is a chronic pain syndrome char-
acterized by widespread pain and stiffness, multiple tender
points, and fatigue [1]. This pain syndrome has an incidence
of 2% in the general population and occurs with higher fre-
quency among women in middle age [2]. FM is often associ-
ated with increased prevalence of depressive symptoms,
major depression and anxiety [3]. The cause and pathophysi-
ology of FMs is unclear; pathophysiological hypotheses
include impairment in the functioning of the hypothalamic-pitu-
itary axis and alterations in specific neurotransmitters such as
substance P, N-methyl-D-aspartate, noradrenaline (norepine-
phrine) and serotonin (5-HT). However, interest has been
growing in a possible involvement of 5-HT in FM. Indeed,
strong evidence has accumulated to support the hypothesis
that a deficiency in serotonergic neuronal functioning might be
related to the pathophysiology of FM [5-8]. Patients with FM
have been found to have decreased concentrations of 5-HT
and tryptophan (5-HT precursor) in serum and cerebrospinal
fluid. 5-HT, in particular, is theorized to have a function in stage
4 sleep and in the pain threshold [9]. This neurotransmitter is
implicated in psychiatric disorders such as depression, anxi-
ety, and obsessive compulsive disorder. Stressful experiences
lead to depression in some people who are already genetically
predisposed, and increase the probability of FM exordium. The
5-HT gene could moderate the serotonergic response to
stress [4].
As a mediator, 5-HT exerts its actions by means of interaction
with distinct receptors, which are differentiated on the basis of
structures, molecular mechanisms and pharmacological pro-
files [9]. On this basis, drugs acting on 5-HT receptors, in par-
ticular on 5-HT2 and 5-HT3, are being used or investigated for
the clinical management of FM [10,11]. Among drugs
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targeting 5-HT receptors, ketanserin is a selective 5-HT2
antagonist that can reduce the hyperalgesia, spontaneous
pain, sleep disorders and other symptoms of FM [12], and
granisetron and tropisetron are selective 5-HT3  receptor
antagonists that show clinical efficacy in FM [11].
In an analogous manner to other transmitters, the endogenous
activity of 5-HT is controlled by a specific 5-HT transporter
(SERT), which mediates the intracellular reuptake of 5-HT and
can be specifically blocked by selective 5-HT reuptake inhibi-
tors (SSRIs) such as paroxetine and fluoxetine. SERT is widely
expressed in intestinal epithelial cells, in central or peripheral
serotonergic neurons and in platelets; it shares common
molecular and physiological features in these locations [13-
15]. Clinical studies have demonstrated the efficacy of SSRI
in FM [16], but the data are not unequivocal. Nociception
refers to the physiological process of transmitting a painful
stimulus from the periphery through afferent neurons to the
cerebral cortex. It has been postulated that serotonergic neu-
rotransmission has a significant function in nociception
[17,18]; alterations in 5-HT metabolism and transmission
might therefore be important in the pathogenesis of FM. These
findings support the proposal that aberrant pain perception in
FM also results from an instability of the 5-HT system in FM.
There is also evidence that changes in the expression of SERT
are due to a polymorphism in the transcription region in
patients with FM [19].
In the present study, both the expression and functionality of
SERT were determined in platelets collected from patients
with FM, with the following aims: first, to perform a comparison
with the pharmacological profile of platelet SERT in healthy
volunteers, and second, to examine putative correlations of
SERT characteristics with the severity of symptoms such as
tiredness, Fibromyalgia Impact Questionnaire (FIQ) score or
tender point index (TPi).
Materials and methods
Materials
[3H]Serotonin (specific radioactivity 30 Ci/mmol) and [3H]par-
oxetine (specific radioactivity 19.1 Ci/mmol) were purchased
from Perkin-Elmer Life Science (Milano, Italy). All other rea-
gents were obtained from normal commercial sources.
Subjects
Forty patients (all female) affected by primary FM, aged 53 ±
13 years (mean ± SD) took part in the study, and 38 healthy
females age-matched to the patients (50 ± 12 years) were
used as a control group. The American College of Rheumatol-
ogy criteria for FM [1] were used to make the diagnosis of FM.
The inclusion criteria for the study groups comprised a nega-
tive history for psychoactive drug treatment and other neuro-
logical disorders. None of the subjects had comorbid
psychiatric disorders or had received treatment with antide-
pressant drugs. No patient was under pharmacological treat-
ment. All patients underwent a wash-out period of 2 months
before the study. They were enrolled at the University Division
of Rheumatology, Santa Chiara Hospital, Pisa. Written con-
sent was obtained from all patients and controls after a full
explanation of the procedure. The study was approved by the
local Ethics Committee.
Evaluation of clinical parameters
For each patient and control, tenderness at tender points was
evaluated by means of the Fischer dolorimeter [20]. The total
fibromyalgic tender point score (right plus left) was used for
statistical analysis. Each positive tender point had a pain score
between 0 (no pain) and 3 (severe pain). We also calculated
the TPi as the sum of the scores of all tender points divided by
the total number of tender points.
To estimate the impact of FM on the quality of life, all patients
and controls received an FIQ [21]. The total score was the
sum of the values of the 10 FIQ items, which reflected the
impact of FM and ranged from 0 (no impact) to 100 (maximum
impact).
Tiredness was evaluated as measured by the FIQ tiredness
item, which consisted of a visual analogic scale numbered
between 0 and 10.
To exclude major psychiatric disorders, all patients were eval-
uated by means of a diagnostic interview consisting of the
administration of the Structured Clinical Interview for DSM-IV
axis-I disorder (SCID-I/P) [22]. This assessment was con-
ducted by psychiatrists who were trained and certified in the
use of the study instruments at our department.
Separation of platelets
Venous blood (30 ml) was collected from each subject and
gently mixed with 1 ml of anticoagulant (0.15 M EDTA). Plate-
let-rich plasma was obtained by low-speed centrifugation
(200g for 20 minutes at 22°C). Platelets were counted auto-
matically with a flux cytometer (Cell-dyn 3500 system; Abbott,
Milano, Italy).
For measurement of [3H]serotonin reuptake, platelets were
used immediately, whereas for [3H]paroxetine binding, plate-
lets were precipitated by centrifugation at 10,000g for 10 min-
Table 1
[3H]Paroxetine binding characteristics in platelet membranes 
of control subjects and patients with fibromyalgia
Variable Controls (n = 38) Patients with FM (n = 40)
Bmax (fmol/mg protein) 1,260 ± 34 1,048 ± 30a
Kd (nM) 0.077 ± 0.012 0.086 ± 0.021
Results are shown as means ± SEM. Bmax, maximal membrane 
binding capacity; FM, fibromyalgia; Kd, dissociation constant. ap < 
0.0001.Available online http://arthritis-research.com/content/8/4/R99
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utes at 4°C and the pellets were then stored at -80°C until the
assay.
[3H]Serotonin uptake
[3H]Serotonin uptake was performed as described by Arora
and Meltzer [23], with some modifications. Aliquots of plate-
lets (2 × 106 platelets) were incubated for 10 minutes at 37°C
with [3H]serotonin at six concentrations from 15 to 700 nM in
an assay buffer (118 mM NaCl, 4.7 mM KCl, 1.07 mM
MgSO4.7H2O, 1.17 mM KH2PO4, 25 mM NaHCO3, 11.6 mM
glucose, pH 7.4, in the presence of 0.1% ascorbate and 100
µM Pargyline) to a final volume of 0.5 ml. Non-specific uptake
was measured in the presence of 10 µM Fluoxetine.
Preparation of platelet membranes
The platelet pellets were washed with 10 ml of buffer (150 mM
NaCl, 20 mM EDTA, 50 mM Tris-HCl, pH 7.4). Pellets were
lysed and homogenized in 10 ml of buffer (5 mM Tris-HCl, 5
mM EDTA, pH 7.4, containing the following protease inhibi-
tors: 200 µg/ml bacitracin, 160 µg/ml benzamidine and 20
µg/ml soybean trypsin inhibitor) with an Ultra-Turrax homoge-
nizer and centrifuged twice at 30,000g for 15 minutes at 4°C.
The resulting pellets were resuspended in ice-cold 50 mM
Tris-HCl buffer, pH 7.4, containing protease inhibitors, and
centrifuged at 50,000g for 15 minutes at 4°C. The pellets
were then suspended with assay buffer (50 mM Tris-HCl, 120
mM NaCl, 5 mM KCl, pH 7.4).
Protein concentration was determined with the method of
Lowry and colleagues [24] using bovine serum albumin as a
standard.
[3H]Paroxetine binding assay to platelet membranes
[3H]Paroxetine binding was performed as described by
Marazziti and colleagues [25]. The incubation mixture con-
sisted of 100 µl of platelet membranes (50 to 100 µg of pro-
tein per tube), 50 µl of [3H]paroxetine at six concentrations
(0.01, 0.025, 0.05, 0.25, 0.5 and 1 nM) and 1.85 ml of assay
buffer. Specific binding was obtained by using 10 µM fluoxet-
ine as a displacer.
Data analysis
Equilibrium-saturation binding data, the maximum binding
capacity (Bmax, fmol/mg of protein) and the dissociation con-
stant (Kd, nM) were analysed by means of the iterative curve-
fitting computer programs EBDA and LIGAND (Kell for Win-
dows, v. 6.0).
The maximal uptake rate of SERT (Vmax, pmol/109 cells per
minute) and the Michaelis constant (Km, nM) were obtained by
direct weighted nonlinear regression of uptake rate against
[3H]serotonin concentration with GraphPad PRISM software
(GraphPad, San Diego, CA, USA).
Statistical analysis was performed with Student's t test. The
relationship between variables was checked with a two-tailed
Spearman analysis.
Results
[3H]Paroxetine binding sites on the SERT of platelet mem-
branes were used as a first marker of serotonergic function.
Table 1 shows the mean Bmax values for the density, and Kd val-
ues for the affinity, of [3H]paroxetine binding on platelets in the
patients and in the healthy controls. A statistically significant
difference was found between the two groups for Bmax (1,048
± 30 versus 1,260 ± 34 fmol/mg for control; mean ± SEM) but
not for Kd (0.086 ± 0.021 nM versus 0.077 ± 0.012 nM for
control; mean ± S.E.M.).
The evaluation of symptom severity in patients with FM (Table
2) yielded tiredness scores from 2 to 10 with a mean of 7.4 ±
2.2 (SD), TPi values from 1 to 3 with a mean of 2.2 ± 0.5 (SD),
and FIQ scores from 8 to 94 with a mean of 57.1 ± 21.3 (SD).
The severity of symptoms was shown to be related to the max-
imal binding capacity of platelet SERT, in that the statistical
analysis showed a negative correlation between symptom
scores and the respective Bmax values (p < 0.0001 for tired-
ness; p < 0.0001 for TPi and p < 0.0001 for FIQ). By contrast,
no significant correlation was found when comparing symp-
tom severity with Kd values.
Age did not seem to influence the binding parameters of plate-
let SERT in either patients with FM or healthy volunteers.
[3H]Serotonin uptake on platelets was used as marker of the
functionality of SERT. Vmax and  Km values of [3H]serotonin
uptake in patients with FM accounted for 90 ± 4 pmol/109
platelets per minute and 96 ± 15 nM, respectively (means ±
SEM; Table 3). A comparison of these parameters with those
in healthy volunteers indicated significant differences for Vmax
values but not for Km values: whereas the mean Vmax in the
patients with FM was significantly lower (90 ± 4 versus 114 ±
6 pmol/109 platelets per minute for controls; p < 0.001), the
mean Km in the patients with FM was not significantly different
(96 ± 15 versus 114 ± 15 nM for controls; Table 2).
The severity of the symptoms was related to Vmax and Km in that
the statistical analysis showed a negative correlation between
the symptom scores and the respective Vmax values (p  <
0.0001 for tiredness; p < 0.05 for TPi and p < 0.001 for FIQ).
We also found a positive correlation between Km values and
tiredness (p < 0.001), TPi (p < 0.001) and FIQ (p < 0.001).
The covariate age was shown not to have an effect on the var-
iability of the Vmax or Km values in either patients with FM or
healthy volunteers.
Discussion
The present study is the first examination of the relationships
between SERT expression and kinetic parameters of 5-HTArthritis Research & Therapy    Vol 8 No 4    Bazzichi et al.
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uptake. We have found statistically significant differences in
Bmax and Vmax values between patients with FM and controls.
Moreover, we found a negative correlation between symptom
scores and the respective Bmax and Vmax values (Bmax and Vmax
versus tiredness, TPi and FIQ score). The platelet is consid-
ered to be a peripheral model of neuronal activity with respect
to 5-HT function. In fact, previous studies have demonstrated
that the same SERT is expressed in the central nervous sys-
tem and platelets [14]. Moreover, the identity between the two
structures, as confirmed by sequence homologies through
cloning studies [15], has provoked a surge of different studies
in neuropsychiatric disorders, given the possibility of exploring
peripherally a mechanism of the central nervous system [26].
Recently it has been proposed that altered serotonergic neu-
ronal function might be related to the pathophysiology of FM
[5,8,27]. These findings prompted us to investigate the char-
acteristics of SERT in the platelets of patients with FM. Bmax
and Kd values of [3H]Paroxetine binding were assumed to rep-
resent SERT density and ligand binding affinity, respectively,
whereas  Vmax and  Km values of [3H]Serotonin uptake were
taken as estimates of SERT rate and affinity, respectively. A
very interesting observation was that both binding and uptake
parameters differed significantly from those of healthy
volunteers.
The patients with FM have fewer SERTs expressed on the cel-
lular membrane than healthy subjects (a decreased Bmax, per-
haps because the SERTs are less transcribed). Besides
having fewer SERTs, patients with FM have a deficit in func-
tionality (demonstrated by a decrease in transport rate).
Such combined changes in Bmax and Vmax values allow the
inference that the efficiency of 5-HT uptake by platelet SERT
is altered. Our previous studies demonstrated an alteration of
SERT density and of the uptake rate of SERT in psychiatric
patients [28,29]. Consistent with this suggestion was the cor-
relation analysis in the present study: the lower the density and
rate of SERT on platelet membranes, the higher the severity of
FM symptoms. Moreover, the Km values were also positively
correlated with tiredness, TPi and FIQ.
A reduced density and rate of SERT are consistent with previ-
ous observations indicating that levels of 5-HT are altered in
patients with FM [30,31]. The biophysiological mechanism of
FM has been proposed to be similar to that in depression, and
it has been suggested that this is likely to result from a neu-
roendocrine/neurotransmitter  dysregulation [32]. However,
we suppose that the alterations in Bmax and Vmax values are not
related to the pathophysiology of FM but are a consequence
of FM. Our hypothesis is that a decrease in Bmax and Vmax of
SERT is due to a pain stimulus [33,34].
It has been shown that the decreased pain perception thresh-
old during depression is likely to result from a dysfunction in
several neurotransmitter systems, especially the serotoniner-
gic one, which is also involved in the pathophysiology of
depression [35]. In addition, an excessive stimulation of
peripheral 5-HT receptors would account for pain and might
explain why the clinical use of 5-HT3 receptor antagonists
such as tropisetron or granisetron can promote the relief of
disturbance associated with FM [11,36].
SERT has been investigated previously in patients with FM,
with discordant results. Russell and colleagues [37] found a
higher  Bmax  in patients with FM than in healthy controls,
whereas other authors found normal Bmax values [28,35] using
[3H]Paroxetine or [3H]Imipramine [38]. In our experiments we
used [3H]Paroxetine, which binds with high affinity to a spe-
cific population of binding sites located on human platelets
and neuronal membranes, associated with 5-HT uptake mech-
anisms [39]. The present results indicate a decrease in the
density and rate of platelet SERT in patients with FM, and
allow us to propose a specific role for SERT in the pathogen-
esis of FM. In fact, we avoided the inclusion of patients with
FM who had psychiatric components because it is known that
in psychiatric disorders such as depression, the expression of
SERT is altered [40-42] and it is very difficult to identify the
role of the two components in patients with FM who have
comorbid psychiatric disorders. Thus, the changes in Bmax and
Vmax demonstrated in our study may be due to FM only.
There is also a possible contribution from 5-HT to the aetiology
of FM because of the efficacy of SSRIs in the management of
chronic pain in idiopathic pain disorders [43]. Thus, in view of
the decreased Bmax and Vmax values found in our subset of
Table 2
Characteristics of control subjects and patients with 
fibromyalgia
Characteristic Healthy controls Patients with FM Reference range
Age (years) 50 ± 12 53 ± 13 -
Sex F F -
Tender points 2 ± 0.5 14.3 ± 3.72 0–18
TPi 1 ± 0.5 2.2 ± 0.5 0–3
FIQ 22.3 ± 16.33 57.1 ± 21.3 0–100
Tiredness 2.73 ± 2.7 7.4 ± 2.2 0–10
Results are means ± SD. FIQ, Fibromyalgia Impact Questionnaire; 
FM, fibromyalgia; TPi, tender point index.
Table 3
Serotonin uptake characteristics in platelets of control 
subjects and patients with fibromyalgia
Variable Controls (n = 38) Patients with FM (n = 40)
Vmax (pmol/109 
platelets per minute)
114 ± 6 90 ± 4a
Km (nM) 114 ± 15 96 ± 15
Results are shown as means ± SEM. FM, fibromyalgia; Km, Michaelis 
constant; Vmax, maximal uptake rate of specific serotonin transporter. 
ap < 0.001.Available online http://arthritis-research.com/content/8/4/R99
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mentally healthy patients, who were SSRI free, we propose
that there is a compensatory mechanism in the central nervous
system to relieve the pain. This may clarify the improvement in
the therapeutic effectiveness of SSRI in the patients with FM.
Conclusion
This is to our knowledge the first observation that, apart from
a decrease in expression, there is also an alteration in the rate
of SERT which seems to depend not only on the SERT
number. In fact, Bmax is not correlated with Vmax (data not
shown).
In the patients with FM, the decrease in 5-HT levels, which had
already been observed, together with the impaired SERT func-
tionality, might contribute to the pathogenesis of the disease,
both in quantity and rate. In fact, these two factors are impor-
tant because they are correlated with the level of disease
severity.
Thus, the results of the present study are in agreement with the
hypothesis that a deficit in the 5-HT transporter site could be
of pathogenetic significance in FM syndrome.
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